Illumina (ILMN) shares rallied 3.3% in the last trading session to close at $134.78. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.4% gain over the past four weeks.Illumina witnessed a strong price rise on investors’ optimism following a collaboration with MyOme, a leading genomics innovation and risk modeling company. Illumina will invest into MyOme to advance the latter’s strategic roadmap including Pro ...

财务业绩 - 公司季度每股收益为1.34美元，超出市场一致预期的1.16美元，同比增长17.5% [1] - 季度收益超出预期15.52%，上一季度收益为1.19美元，超出预期16.67% [1] - 在过去四个季度中，公司三次超出每股收益预期 [2] - 季度营收为10.8亿美元，超出市场一致预期1.73%，与去年同期持平 [2] - 在过去四个季度中，公司四次超出营收预期 [2] 市场表现与展望 - 公司股价年初至今下跌约28.9%，同期标普500指数上涨17.2% [3] - 当前市场对下一季度的共识预期为每股收益1.18美元，营收11亿美元 [7] - 当前财年共识预期为每股收益4.49美元，营收42.6亿美元 [7] 行业比较 - 公司所属的医疗-生物医学和遗传学行业在250多个Zacks行业中排名前38% [8] - 同行业公司Coherus Oncology预计季度每股亏损0.34美元，同比变化-3300% [9] - Coherus Oncology预计季度营收为1221万美元，同比下降82.8% [9]